Psyence Completes US$2.6M PsyLabs Backstop as Ibogaine Milestones Met
PBM has more than doubled off its 52-week low of $1.92.
Summary
Psyence completed its final US$2.6M backstop investment in related party PsyLabs after both ibogaine milestones were certified, lifting its stake to about 43.37% and using existing cash to fund it.
Key Events · M&A and Partnerships · PBM
-
PsyLabs Backstop Fully Funded
Psyence Biomed II Corp. subscribed for 1,014 PsyLabs ordinary shares at US$2,564 each, for US$2,599,896, completing the up-to-US$5M commitment announced September 23, 2026.
-
Stake Rises to 43.37%
Psyence's PsyLabs ownership moved from about 41.13% to about 43.37% after the investment and the October 1, 2026 share exchange.
-
Ibogaine Milestones Certified
PsyLabs completed its ibogaine regulatory readiness documentation package and TIRC executed a cGMP manufacturing agreement with DEA-registered Benuvia in Round Rock, Texas.
-
Cash Used, Not New Capital
The US$2.6M was funded from existing cash resources, reducing Psyence's liquidity while adding an illiquid stake in a private related party.
Analysis · PBM · Life Sciences
The full US$5M PsyLabs commitment is now funded, with the final US$2.6M tranche triggered by two milestones: PsyLabs finishing its ibogaine regulatory readiness pack and TIRC signing a cGMP manufacturing deal with DEA-registered Benuvia. That lifts the stake in PsyLabs to about 43.37%, but the cash came out of Psyence's own balance sheet, so the company is trading liquidity for a larger slice of a private, illiquid related party. The next hard date is the definitive TIRC-PsyLabs supply agreement, targeted on or before November 30, 2026.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.2% of the 1544 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $1.92 to $22.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.